Pressrelease 28 September 2006
Glucox' Unique Research Discovery Confirmed by US Scientist
“This is an important step towards a drug treatment for Diabetes” says Mona Wilcke, CEO of the Swedish biotechnology company Glucox Biotech.
An American research group led by professor C S Stump has convincingly shown in the last issue of the respected scientific periodical Journal of Biological Chemistry, JBC, that one of the underlying mechanism for type 2-diabetes may be abnormal activity levels of an enzyme in the cellular energy metabolism, NADPH-oxidase. The Swedish company Glucox Biotech owns the patent rights for this enzyme.
Since three years, Glucox works on developing a therapeutic drug against diabetes on this particular enzyme. The work of Glucox is concentrated to discovering drug candidates that shall reduce the activity of this enzyme in a specific and safe manner.
Recently, Glucox Biotech submitted a novel patent application covering the exclusive right to apply these drug substances for treatment of diabetes.
Download a pdf of the Pressrelease
Pressrelease 15 May 2007
Promising Results in Treatment with GLX
Pressrelease 29 December 2006
US Patent Received for Diabetes Treatment
Pressrelease 28 September 2006
Glucox' Unique Research Discovery Confirmed by US Scientist
Pressrelease 10 July 2006
Patent Application Submitted for the GLX Compounds
Pressrelease 5 June 2006
A Significant Preclinical Milestone Achieved
Pressrelease 7 February 2006
Positive Results from the First Time In Animal Study
Pressrelease 10 January 2006
Pressrelease 10 November 2005
Evaluation and Selection of Glucox Biotech' Lead Drug Candidates